Loading organizations...
§ Private Profile · Berkeley, CA, USA
Biopharmaceutical company developing and commercializing clinical-stage products, focused on respiratory and allergic diseases.
Aerovance was a Berkeley, California-based biopharmaceutical company led by prominent industry executives and strategic decision-makers such as Mark Perry, William Newell, and Christopher Busse. The enterprise developed and commercialized clinical-stage therapeutic products specifically designed for the treatment of severe respiratory and allergic diseases. The organization primarily focused its research and development efforts on creating targeted medical interventions for complex patient conditions, including uncontrolled asthma, eczema, cystic fibrosis, and chronic obstructive pulmonary disease. Aerovance was officially founded during 2004 when it was established as an independent corporate spin-off originating directly from the global pharmaceutical giant Bayer Healthcare. Before the business ultimately reached the end of its lifecycle and ceased all operations, the enterprise successfully secured an impressive total of $150.5 million in venture capital and spin-off financing to advance its clinical pipeline.
Aerovance has raised $130.0M across 3 funding rounds.
Aerovance has raised $130.0M in total across 3 funding rounds.
Aerovance has raised $130.0M in total across 3 funding rounds.
Aerovance's investors include Nest.Bio Labs.
Aerovance has raised $130.0M across 3 funding rounds. Most recently, it raised $38.0M Series U in April 2009.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2009 | $38M Series U | — | Nest.bio Labs | Announced |
| Mar 1, 2007 | $60M Series C | — | Nest.bio Labs | Announced |
| Aug 1, 2004 | $32M Series B | — | Nest.bio Labs | Announced |
Aerovance is a biopharmaceutical company developing biologics and clinical-stage therapies for respiratory, allergic, and inflammatory diseases, such as asthma and atopic dermatitis.[1][3][4] Its pipeline includes drugs like Pitrakinra, an IL-13R and IL-4Rα inhibitor that reached pending or discontinued phases for indications like dermatitis.[3] Originally focused on respiratory biologics since 2004, conflicting sources note a technology platform for converting injectable drugs to oral forms, though primary emphasis remains on disease-specific treatments.[2][4] The company serves patients with unmet needs in these areas, advancing four drugs into mid-stage development from Berkeley, California (with some mentions of Worcester, Massachusetts).[2][4][5]
Founded in 2004, Aerovance emerged as a start-up biotech firm with researchers targeting biologics for inflammatory and respiratory diseases.[4] Key early focus included advancing multiple drug candidates into clinical stages, with Pitrakinra entering trials as early as November 2007 and March 2009 for atopic dermatitis and related conditions.[3] Headquartered in Berkeley, United States, the company built traction through a mid-stage pipeline, though specific founders are not detailed in available records.[5][6] Pivotal moments involved progressing four therapies, positioning it as an innovator in biologics despite later pipeline discontinuations.[3][4]
Aerovance rides the trend of biologics innovation in respiratory and immunology markets, where inflammatory diseases affect millions and demand targeted therapies amid rising allergies and asthma prevalence.[1][4] Timing aligns with early 2000s biotech boom in protein-based drugs, influencing the ecosystem by contributing to IL-4/IL-13 inhibitor research that paved the way for approved treatments like dupilumab.[3] Market forces favoring it include unmet needs in oral alternatives to injectables and a shift toward patient-centric delivery, though pipeline setbacks highlight biotech risks like trial discontinuations.[2][3]
Aerovance's legacy in respiratory biologics underscores early promise in immunology, but discontinued pipeline elements like Pitrakinra suggest acquisition or pivot potential rather than standalone growth.[3] Next steps could involve licensing tech for oral conversions amid trends in drug reformulation and AI-driven biotech revival.[2] Its influence may evolve through foundational contributions to allergy treatments, tying back to its role as a 2000s pioneer advancing clinical-stage hope for respiratory patients.[1][4]